Rheumatoid Arthritis Information
More articles below:
Rheumatoid Arthritis a Threat to the Heart
Vaccine Reverses Type 1 Diabetes in Mice
Middle-Age Americans Less Mobile Than Ever
Long-Term Methotrexate Won't Help Kids With Juvenile Arthritis
Obesity, Alcohol Among Factors Linked to Women's Gout Risk
Many With Arthritis Find Simple Solutions for Relief
New Drug Shows Promise for Rheumatoid Arthriitis
FRIDAY, June 26 (HealthDay News) -- A new drug to treat rheumatoid arthritis reduces joint inflammation in severe cases while causing only mild to moderate side effects, according to a report from the first clinical trial of the drug on humans.
Masitinib, which is being developed by AB Science pharmaceuticals, is supposed to halt the activity of mast cells, a part of the immune system believed to be involved in the start and progression of rheumatoid arthritis.
The results of the French trial, involving 43 people with arthritis that other treatments had failed to help, appears online in Arthritis Research and Therapy.
"We are encouraged from this study that masitinib not only appears to be effective, but that within the first three months of treatment, the worst of its side effects were over, possibly making it suitable for long-term treatment regimens," one of the researchers, Olivier Hermine, said in a news release from the journal's publisher. The next step will be placebo-controlled trials, he added.
More information
The Arthritis Foundation has more about rheumatoid arthritis.
DON'T HAVE Rx COVERAGE?Click Here to print out your FREE OPTIMIZERx Card and instantly begin savings on your next prescriptions!
